Chemical Namepitolisant
Dosage FormTablet (oral; 4.45 mg, 17.8 mg)
Drug ClassReceptor antagonists
CompanyHarmony Biosciences
Approval Year2019


  • Wakix is indicated for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy.
Last updated on 11/9/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Wakix (pitolisant) Prescribing Information 2019Harmony Biosciences